Last reviewed · How we verify

Monoferric — Competitive Intelligence Brief

Monoferric (FERRIC DERISOMALTOSE) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Hematology.

marketed Serotransferrin Hematology Oligosaccharide Live · refreshed every 30 min

Target snapshot

Monoferric (FERRIC DERISOMALTOSE) — Pharmacosmos. Monoferric works by binding to serotransferrin, a protein that transports iron in the body, allowing it to be absorbed and utilized by red blood cells.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Monoferric TARGET FERRIC DERISOMALTOSE Pharmacosmos marketed Serotransferrin 2020-01-01
Monoferric Monoferric Brigham and Women's Hospital marketed Serotransferrin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Monoferric — Competitive Intelligence Brief. https://druglandscape.com/ci/ferric-derisomaltose. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: